Gastroenteropancreatic neuroendocrine tumors: Incidence and treatment outcome in a single institution in Korea

Aim:  We studied to identify the clinicopathological features, treatment outcome, and prognostic factors for patients with gastrointestinal and hepatopancreaticobiliary neuroendocrine tumor (NET). Method:  Between February 2001 and May 2006, a total of 470 patients were diagnosed with NET arising fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asia-Pacific journal of clinical oncology 2011-09, Vol.7 (3), p.293-299
Hauptverfasser: LIM, Taekyu, LEE, Jeeyun, KIM, Jae J, LEE, Jong Kyun, LEE, Kyu Taek, KIM, Young Ho, KIM, Kwang-Won, KIM, Sung, SOHN, Tae Sung, CHOI, Dong Wook, CHOI, Seong Ho, CHUN, Ho-Kyung, LEE, Woo Young, KIM, Kyoung-Mee, JANG, Kee-Taek, PARK, Young Suk
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aim:  We studied to identify the clinicopathological features, treatment outcome, and prognostic factors for patients with gastrointestinal and hepatopancreaticobiliary neuroendocrine tumor (NET). Method:  Between February 2001 and May 2006, a total of 470 patients were diagnosed with NET arising from the gastrointestinal tract, pancreas, and hepatobiliary system. The retrospective patient cohort was obtained and analyzed. Results:  The male to female ratio was 1.5:1, and the median age was 55 years (range, 16–81). The most common primary site was the rectum (55.8%). Overall 29 (6.2%) originated from the hepatobiliary system. At initial presentation, 60 patients (12.8%) showed distant metastases. Curative surgery or endoscopic resection was performed in 401 patients. Histopathological distributions were as follows: well differentiated tumor (82.1%), well differentiated carcinoma (10.2%) and poorly differentiated carcinoma (7.7%). The frequency of the poorly differentiated type was somewhat higher in the hepatobiliary system than in the pancreas and gastrointestinal tract (44.8, 15.4 and 2.8%, respectively, P 
ISSN:1743-7555
1743-7563
DOI:10.1111/j.1743-7563.2011.01423.x